Valneva SE Valneva SE

Valneva SE

VLA

Rank in Stocks #11696
Valneva SE is a specialized biotechnology company focused on developing and... Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.
Share Price
$2.84
Last synced: 2026-11-13
Market Cap
$538.49M
Change (1 day)
-2.67%
Change (1 year)
-35.13%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Valneva SE (VLA)
Operating Margin as of November 2026 TTM: -86.68%
According to Valneva SE's latest financial reports, its current operating margin (TTM) is -86.68%. At the end of 2025 the company had an operating margin of -46.74%.
Operating Margin history for Valneva SE from 2005 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -86.68% 85.45%
2025 -46.74% -694.66%
2024 7.86% -114.72%
2023 -53.40% 70.06%
2022 -31.40% 78.00%
2021 -17.64% -64.68%
2020 -49.95% -4,297.48%
2019 1.19% -78.52%
2018 5.54% -247.34%
2017 -3.76% -91.69%
2016 -45.26% 77.91%
2015 -25.44% -60.56%
2014 -64.50% -5.84%
2013 -68.50% -81.69%
2012 -374.03% 762.42%
2011 -43.37% -56.74%
2010 -100.26% -50.69%
2009 -203.33% 120.34%
2008 -92.28% -83.30%
2007 -552.54% 5,722.34%
2006 -9.49% -80.02%
2005 -47.49% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -97.75%
US
33.87% -100.39%
US
-116.04% -98.66%
US
25.57% -100.29%
AU
31.23% -100.36%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Valneva SE's operating margin

What is Valneva SE's operating margin?

Valneva SE's operating margin is -86.68%, as of Nov 2026.

What was Valneva SE's operating margin in 2025?

In 2025, Valneva SE's operating margin was -46.74%, compared with 7.86% in 2024.

How has Valneva SE's operating margin changed since 2020?

From 2020 to 2025, Valneva SE's operating margin was highest in 2024 (7.86%) and lowest in 2023 (-53.40%).

How does Valneva SE's operating margin compare with similar companies?

Valneva SE's operating margin (-86.68%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.